Restarting Selumetinib Promising for Recurrent Low-Grade Glioma in Kids

Retreatment with the MEK inhibitor selumetinib (Koselugo) shows promise for children with recurrent low-grade glioma, according to prospective evidence presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO).